seattle times news from FierceBiotech
News
CellCyte in 'precarious' shape after shares collapse
After a brief period as a high-flying stem cell company, CellCyte Genetics' share price Read more...
Fledgling Recodagen gets first venture round
Seattle's Accelerator has a new fledgling biotech company on its hands. Recodagen is taking flight with an undisclosed amount of money from a Series A venture round. The cash is coming from Read more...
ALSO NOTED: ZymoGenetics to chop jobs; Evotec extends collaboration; Iomai touts results for vaccine patch; and much more...
> ZymoGenetics is chopping 80 jobs--mostly in R&D--after facing some tough reviews for the potential of its newly released drug Recothrom--a genetically engineered form of thrombin to prevent Read more...
Cell Therapeutics reorganizes, scales back R&D
Cell Therapeutics is scaling back its research plans for Xyotax and pixantrone, cutting one group of Read more...
Omeros lays plans for $115M stock offering
Seattle-based Omeros has blueprinted plans for an IPO to raise $115 million. Omeros is betting that its experimental therapies for inflammation and CNS disorders can snag investors' dollars to Read more...
Report: CellCyte stock up after promoter touts shares
After struggling for years to survive on angel investments, the Seattle Times reports that CellCyte Genetics has ridden a wave of hype this fall to push its market value to $440 million. And the Read more...
Gene therapy trial to resume after patient's death
The gene therapy field is breathing a mighty sigh of relief after Targeted Genetics Read more...
Seattle start-up gains $30M in second venture round
Another biotech graduate of the Seattle incubator Accelerator Corp. has won a significant round of venture backing. Allozyne says that it has garnered a $30 million Series B, enough money to take a Read more...
Expert panel rejects pleas for Hemopure trial
Rejecting the strenuous pleas of the U.S. Navy, an FDA advisory panel has rejected Biopure's bid to test the blood substitute Hemopure on civilian trauma patients. Voting 11 to eight against the move, the experts concluded that the risks exceeded the potential benefits of the trial. Blood substitutes are a highly controversial therapy, in large part because they need to be tested on trauma victims without their consent. The Navy has been backing Biopure's program, though, saying that a …
Read more...Study shows that Alzheimer's drugs don't work
The primary drugs used to treat a wide range of symptoms of Alzheimer's--including agitation, aggression and hallucinations--are no better than placebos. That's the conclusion of researchers involved in a 33-site study of Zyprexa, Seroquel and Risperdal. Up to half of the patients in the study stopped taking the drugs because they weren't working and up to 24 percent stopped because of side effects. Scientists said the data showed that a new generation of therapies need to be developed …
Read more...Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets